Rob Abrams
Finding Funding for Your Idea
Rob Abrams has over 27 years of experience in biomedical device product development, research, operational management, new business development and strategic investments. Rob joined Sanderling as an Operating Partner in April 2008, where he currently serves as CEO of Pulsar Vascular, Inc. & Theregen, Inc.
Prior to joining Sanderling, Rob served 12 years at Boston Scientific Corp. as Group Vice President of New Business Development for BSC’s Cardiovascular Group Divisions, which included Neurovascular, Cardiac Surgery, Neuromodulation, Electrophysiology, and Peripheral Interventional Divisions. In this role, he also served on executive management boards, and patent and legal review boards. During his tenure at BSC, Rob completed acquisition of Smart Therapeutics, Inc. for intracranial stents, and other minimally invasive access devices, Precision Vascular Systems, Inc. a steerable guidewire/catheter company, and several neuromodulation companies, including acquisition of Advanced Bionics Corp. He also led the corporate program to explore technology for acute ischemic stroke therapy, and transacted several investments in that realm. Rob had become a part of BSC via their acquisition of Target Therapeutics, where he was Director of New Business Development from July 1996.
Course Syllabus click here
